| Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq I Tirosh, B Izar, SM Prakadan, MH Wadsworth, D Treacy, JJ Trombetta, ... Science 352 (6282), 189-196, 2016 | 3925 | 2016 |
| Next-generation characterization of the cancer cell line encyclopedia M Ghandi, FW Huang, J Jané-Valbuena, GV Kryukov, CC Lo, ... Nature 569 (7757), 503-508, 2019 | 2464 | 2019 |
| Phenotypic characterization of a comprehensive set of MAPK1/ERK2 missense mutants L Brenan, A Andreev, O Cohen, S Pantel, A Kamburov, D Cacchiarelli, ... Cell reports 17 (4), 1171-1183, 2016 | 152 | 2016 |
| Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies A Hegde, AY Andreev-Drakhlin, J Roszik, L Huang, S Liu, K Hess, ... ESMO open 5 (5), e000799, 2020 | 52 | 2020 |
| Hallmarks of RET and Co-occuring Genomic Alterations in RET-aberrant Cancers JJ Adashek, AP Desai, AY Andreev-Drakhlin, J Roszik, GJ Cote, ... Molecular cancer therapeutics 20 (10), 1769-1776, 2021 | 26 | 2021 |
| Systemic and CNS activity of selective RET inhibition with selpercatinib (LOXO-292) in a patient with RET-mutant medullary thyroid cancer with extensive CNS metastases A Andreev-Drakhlin, M Cabanillas, B Amini, V Subbiah JCO precision oncology 4, 2020 | 26 | 2020 |
| A chemical screen identifies small molecules that regulate hepcidin expression V Gaun, B Patchen, J Volovetz, AW Zhen, A Andreev, MP Pollastri, ... Blood Cells, Molecules, and Diseases 53 (4), 231-240, 2014 | 25 | 2014 |
| The evolving treatment landscape of advanced urothelial carcinoma AY Andreev-Drakhlin, G Egoryan, AY Shah, P Msaouel, O Alhalabi, J Gao Current opinion in oncology 33 (3), 221-230, 2021 | 9 | 2021 |
| Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes O Alhalabi, AW Hahn, P Msaouel, AY Andreev-Drakhlin, ... Molecular Cancer Research 19 (3), 395-402, 2021 | 7 | 2021 |
| Efficacy of immune checkpoint blockade in patients with advanced upper tract urothelial cancer and mismatch repair deficiency or microsatellite instability (MSI). A Andreev-Drakhlin, AY Shah, AC Adriazola, L Shaw, L Lopez, M James, ... Journal of Clinical Oncology 39 (6_suppl), 487-487, 2021 | 6 | 2021 |
| The landscape of RET alterations from 56,970 adult patients with cancer: Clinical implications. A Andreev-Drakhlin, J Roszik, V Subbiah Journal of Clinical Oncology 37 (15_suppl), 3106-3106, 2019 | 3 | 2019 |
| Platinum ineligibility and survival outcomes in patients with advanced urothelial carcinoma receiving first-line treatment S Gupta, A Andreev-Drakhlin, O Fajardo, M Fassò, JA Garcia, C Wee, ... JNCI: Journal of the National Cancer Institute 116 (4), 547-554, 2024 | 2 | 2024 |
| 2409TiP A global, multicentre, open-label, randomised phase II trial of tobemstomig (tobe) with or without tiragolumab (tira) vs atezolizumab (atezo) in patients (pts) with … S Gupta, O Alhalabi, A Bamias, J Bellmunt, DEC Gauna, J Bedke, ... Annals of Oncology 34, S1225, 2023 | 1 | 2023 |
| Levelling the Evidence: A Comparison of Neoadjuvant and Adjuvant Treatment for Upper Tract Urothelial Carcinoma. A Andreev-Drakhlin, J Gao, A Siefker-Radtke European urology 79 (5), 655-656, 2020 | 1 | 2020 |
| The landscape of 2,706 RET alterations from 89,754 adult patients with cancer: Clinical implications JJ Adashek, A Andreev-Drakhlin, J Roszik, AP Desai, V Subbiah Cancer Research 81 (13_Supplement), 1221-1221, 2021 | | 2021 |
| Chemistry of Caring: Timeless Lessons From Oncology Fellowship AY Andreev-Drakhlin, DE Epner Journal of Clinical Oncology 38 (18), 2107, 2020 | | 2020 |
| Massively parallel identification of conserved drug resistant mutations in kinases NS Persky, D Hernandez, J Cordova, A Walker, L Brenan, F Piccioni, ... Cancer Research 78 (13_Supplement), 1815-1815, 2018 | | 2018 |
